HIV protease inhibitor ritonavir induces cytotoxicity of human endothelial cells.
about
In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cellsScutellaria baicalensis decreases ritonavir-induced nauseaThe roles of HIV-1 proteins and antiretroviral drug therapy in HIV-1-associated endothelial dysfunctionInhibition of adenine nucleotide translocator pore function and protection against apoptosis in vivo by an HIV protease inhibitorBiomarkers of vascular dysfunction in children infected with human immunodeficiency virus-1.Heart and HAART: Two sides of the coin for HIV-associated cardiology issuesCUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.Post-exercise heart rate recovery in HIV-positive individuals on highly active antiretroviral therapy. Early indicator of cardiovascular disease?The role of pharmacological enhancement in protease inhibitor-based highly active antiretroviral therapy.Metabolic abnormalities and viral replication are associated with biomarkers of vascular dysfunction in HIV-infected children.Antitumour effects of antiretroviral therapy.Cellular mechanisms of insulin resistance, lipodystrophy and atherosclerosis induced by HIV protease inhibitors.Development of a Tumour Growth Inhibition Model to Elucidate the Effects of Ritonavir on Intratumoural Metabolism and Anti-tumour Effect of Docetaxel in a Mouse Model for Hereditary Breast Cancer.Heme oxygenase-1-derived bilirubin counteracts HIV protease inhibitor-mediated endothelial cell dysfunctionInflammation, immune activation, and cardiovascular disease in HIV.Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s.Effects of ritonavir on adipocyte gene expression: evidence for a stress-related responseLeft ventricular dysfunction in human immunodeficiency virus infection.Antiretroviral compounds and cholesterol efflux from macrophages.Risk of coronary heart disease in patients with HIV infection.Neurotoxicity in the Post-HAART Era: Caution for the Antiretroviral Therapeutics.Premature and accelerated aging: HIV or HAART?Ritonavir increases CD36, ABCA1 and CYP27 expression in THP-1 macrophages.Ritonavir inhibits intratumoral docetaxel metabolism and enhances docetaxel antitumor activity in an immunocompetent mouse breast cancer model.Unusual Response of Subclavian In-Stent Restenosis to Balloon Angioplasty in a Patient with HIV.Effect of antiretroviral therapy on inflammatory markers of endothelial dysfunction in HIV treatment-naïve infected patients.Ginsenosides block HIV protease inhibitor ritonavir-induced vascular dysfunction of porcine coronary arteries.Possible differential induction of phase 2 enzyme and antioxidant pathways by american ginseng, Panax quinquefolius.
P2860
Q24674939-02E738F7-8269-430E-BABE-0D48A21EB8EBQ25257431-60A9FE3E-1257-4483-8879-71E312A8AB5DQ28386344-B5F01350-0C32-4A23-A87A-3772E4AD0883Q33840412-4E7D0F8D-A938-4BF1-BABB-E9E56C8460E3Q34147987-B7E845D7-B0F4-4219-8962-2F660F4F8A84Q34390565-9CFA04A0-1ED2-4485-8741-D8FBE0335C1FQ34437996-22BB7E20-4B33-412A-B0AE-4FED2C7847FAQ34979921-B7EB3C9F-3F66-496B-9F14-471C3C7079ABQ35073349-24213338-0883-44C4-9FC9-212A03684FE8Q35815450-F1254435-A1BA-4233-B128-B7D04C7615E0Q35934144-5E74F86E-6DAC-4DE2-9813-51374705631DQ36011828-7797F5F4-6585-4BE3-A9BC-CD934715A7F0Q36653951-7A51C6DB-D705-436D-8FA2-5D8684F59E38Q36835027-0FBF9FEC-2EDB-46A3-9C71-5D01233EF559Q36957752-3C50594A-2A25-4D00-A0F8-805224F64248Q37016796-C01C5636-C2BE-47BF-90A1-4ACB8042F332Q37038292-03F9758B-D633-4EB4-80A6-F2B95ADA78AAQ37153504-2426338B-43F3-41EC-84AC-634D53B49FC4Q37376313-8B02B1D6-0CFA-47B7-8346-D58C82F02867Q38261508-4E562DFC-0438-4621-85B8-FBC25E230799Q38882614-20D4F730-618A-4D8D-9F45-66EDD1F23B71Q39474417-6BBA6A75-5F15-489A-9B85-CD2C0EBC281CQ39930180-B3CAC963-0BEA-4476-8A88-B455596DE43EQ40617502-41BB3D6C-AE07-4786-A789-934ADB2A40E2Q41429855-DA9C430A-E325-4F03-8883-D2F2FD124459Q44770142-B1168BD1-9ED9-4944-86EC-50E3809A42BDQ45244983-A54E219C-C2AF-4CEF-AB71-8231AB1C551CQ46719094-A563FFBF-48A4-4FDA-A9C2-E6E6A89F608D
P2860
HIV protease inhibitor ritonavir induces cytotoxicity of human endothelial cells.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
HIV protease inhibitor ritonavir induces cytotoxicity of human endothelial cells.
@en
type
label
HIV protease inhibitor ritonavir induces cytotoxicity of human endothelial cells.
@en
prefLabel
HIV protease inhibitor ritonavir induces cytotoxicity of human endothelial cells.
@en
P2093
P1476
HIV protease inhibitor ritonavir induces cytotoxicity of human endothelial cells.
@en
P2093
Alan B Lumsden
Brian S Conklin
Changyi Chen
Dian-sheng Zhong
Peter H Lin
Xiang-huai Lu
P304
P356
10.1161/01.ATV.0000034707.40046.02
P407
P577
2002-10-01T00:00:00Z